Ignite Creation Date:
2025-12-24 @ 4:16 PM
Ignite Modification Date:
2026-05-18 @ 12:58 PM
Study NCT ID:
NCT04844866
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2021-03-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Sponsor:
Miltenyi Biomedicine GmbH
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Diffuse Large B-cell Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CAR T cells | View |
| None | chimeric antigen receptor | View |
| None | MB-CART2019.1 | View |
| None | CD20 | View |
| None | CD19 | View |
| None | relapsed refractory | View |
| None | Diffuse Large B-cell Lymphoma | View |
| None | DLBCL | View |
| None | Non-Hodgkin Lymphoma | View |
| None | NHL | View |
| None | zamtocabtagene autoleucel | View |
| None | blood cancer | View |
| None | LBCL | View |